799-6397288-2/10002/1

Novartis Pharma Gmbh — FEI 3002532211

Refusal Details

Date
November 21, 2025
Country
Germany
Product Category
Drugs and Biologics
Product Code
58ACP04 OMALIZUMAB
Charges
336,472,75